Presage Announces FDA Study May Proceed to Evaluate Candidate in CIVO Ph 0 Trial
16 Jan 2024 //
PR NEWSWIRE
Presage Completes First Phase 0 to Enable Evaluation of Immuno-Oncology Drug
28 Nov 2022 //
BIOSPACE
16 Jan 2024 //
PR NEWSWIRE
28 Nov 2022 //
BIOSPACE